Publication | Open Access

Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma

MedicineImmunologyColorectal CancerAdvanced Colorectal CarcinomaImmune Checkpoint InhibitorClinical EffectsMonoclonal AntibodyImmunotherapyOncologyRadiation OncologyTumor MicroenvironmentCancer Research